Cargando…

Extended effects of a wearable sensory prosthesis on gait, balance function and falls after 26 weeks of use in persons with peripheral neuropathy and high fall risk—The walk2Wellness trial

BACKGROUND: We recently reported that individuals with impaired plantar sensation and high fall risk due to sensory peripheral neuropathy (PN) improved gait and balance function following 10 weeks of use of Walkasins(®), a wearable lower limb sensory prosthesis that provides directional specific mec...

Descripción completa

Detalles Bibliográficos
Autores principales: Oddsson, Lars I. E., Bisson, Teresa, Cohen, Helen S., Iloputaife, Ikechukwu, Jacobs, Laura, Kung, Doris, Lipsitz, Lewis A., Manor, Brad, McCracken, Patricia, Rumsey, Yvonne, Wrisley, Diane M., Koehler-McNicholas, Sara R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531134/
https://www.ncbi.nlm.nih.gov/pubmed/36204554
http://dx.doi.org/10.3389/fnagi.2022.931048
_version_ 1784801837507936256
author Oddsson, Lars I. E.
Bisson, Teresa
Cohen, Helen S.
Iloputaife, Ikechukwu
Jacobs, Laura
Kung, Doris
Lipsitz, Lewis A.
Manor, Brad
McCracken, Patricia
Rumsey, Yvonne
Wrisley, Diane M.
Koehler-McNicholas, Sara R.
author_facet Oddsson, Lars I. E.
Bisson, Teresa
Cohen, Helen S.
Iloputaife, Ikechukwu
Jacobs, Laura
Kung, Doris
Lipsitz, Lewis A.
Manor, Brad
McCracken, Patricia
Rumsey, Yvonne
Wrisley, Diane M.
Koehler-McNicholas, Sara R.
author_sort Oddsson, Lars I. E.
collection PubMed
description BACKGROUND: We recently reported that individuals with impaired plantar sensation and high fall risk due to sensory peripheral neuropathy (PN) improved gait and balance function following 10 weeks of use of Walkasins(®), a wearable lower limb sensory prosthesis that provides directional specific mechanical tactile stimuli related to plantar pressure measurements during standing and walking (RxFunction Inc., Eden Prairie, MN, United States). Here, we report 26-week outcomes and compare pre- and in-study fall rates. We expected improvements in outcomes and reduced fall rates reported after 10 weeks of use to be sustained. MATERIALS AND METHODS: Participants had clinically diagnosed PN with impaired plantar sensation, high fall risk (Functional Gait Assessment, FGA score < 23) and ability to sense tactile stimuli above the ankle at the location of the device. Additional outcomes included 10 m Gait Speed, Timed Up and Go (TUG), Four-Stage Balance Test, and self-reported outcomes, including Activities-Specific Balance Confidence scale and Vestibular Disorders Activities of Daily Living Scale. Participants tracked falls using a calendar. RESULTS: We assessed falls and self-reported outcomes from 44 individuals after 26 weeks of device use; 30 of them conducted in-person testing of clinical outcomes. Overall, improvements in clinical outcomes seen at 10 weeks of use remained sustained at 26 weeks with statistically significant increases compared to baseline seen in FGA scores (from 15.0 to 19.2), self-selected gait speed (from 0.89 to 0.97 m/s), and 4-Stage Balance Test (from 25.6 to 28.4 s), indicating a decrease in fall risk. Non-significant improvements were observed in TUG and fast gait speed. Overall, 39 falls were reported; 31 of them did not require medical treatment and four caused severe injury. Participants who reported falls over 6 months prior to the study had a 43% decrease in fall rate during the study as compared to self-report 6-month pre-study (11.8 vs. 6.7 falls/1000 patient days, respectively, p < 0.004), similar to the 46% decrease reported after 10 weeks of use. CONCLUSION: A wearable sensory prosthesis can improve outcomes of gait and balance function and substantially decreases incidence of falls during long-term use. The sustained long-term benefits in clinical outcomes reported here lessen the likelihood that improvements are placebo effects. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, identifier #NCT03538756.
format Online
Article
Text
id pubmed-9531134
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95311342022-10-05 Extended effects of a wearable sensory prosthesis on gait, balance function and falls after 26 weeks of use in persons with peripheral neuropathy and high fall risk—The walk2Wellness trial Oddsson, Lars I. E. Bisson, Teresa Cohen, Helen S. Iloputaife, Ikechukwu Jacobs, Laura Kung, Doris Lipsitz, Lewis A. Manor, Brad McCracken, Patricia Rumsey, Yvonne Wrisley, Diane M. Koehler-McNicholas, Sara R. Front Aging Neurosci Neuroscience BACKGROUND: We recently reported that individuals with impaired plantar sensation and high fall risk due to sensory peripheral neuropathy (PN) improved gait and balance function following 10 weeks of use of Walkasins(®), a wearable lower limb sensory prosthesis that provides directional specific mechanical tactile stimuli related to plantar pressure measurements during standing and walking (RxFunction Inc., Eden Prairie, MN, United States). Here, we report 26-week outcomes and compare pre- and in-study fall rates. We expected improvements in outcomes and reduced fall rates reported after 10 weeks of use to be sustained. MATERIALS AND METHODS: Participants had clinically diagnosed PN with impaired plantar sensation, high fall risk (Functional Gait Assessment, FGA score < 23) and ability to sense tactile stimuli above the ankle at the location of the device. Additional outcomes included 10 m Gait Speed, Timed Up and Go (TUG), Four-Stage Balance Test, and self-reported outcomes, including Activities-Specific Balance Confidence scale and Vestibular Disorders Activities of Daily Living Scale. Participants tracked falls using a calendar. RESULTS: We assessed falls and self-reported outcomes from 44 individuals after 26 weeks of device use; 30 of them conducted in-person testing of clinical outcomes. Overall, improvements in clinical outcomes seen at 10 weeks of use remained sustained at 26 weeks with statistically significant increases compared to baseline seen in FGA scores (from 15.0 to 19.2), self-selected gait speed (from 0.89 to 0.97 m/s), and 4-Stage Balance Test (from 25.6 to 28.4 s), indicating a decrease in fall risk. Non-significant improvements were observed in TUG and fast gait speed. Overall, 39 falls were reported; 31 of them did not require medical treatment and four caused severe injury. Participants who reported falls over 6 months prior to the study had a 43% decrease in fall rate during the study as compared to self-report 6-month pre-study (11.8 vs. 6.7 falls/1000 patient days, respectively, p < 0.004), similar to the 46% decrease reported after 10 weeks of use. CONCLUSION: A wearable sensory prosthesis can improve outcomes of gait and balance function and substantially decreases incidence of falls during long-term use. The sustained long-term benefits in clinical outcomes reported here lessen the likelihood that improvements are placebo effects. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, identifier #NCT03538756. Frontiers Media S.A. 2022-09-20 /pmc/articles/PMC9531134/ /pubmed/36204554 http://dx.doi.org/10.3389/fnagi.2022.931048 Text en Copyright © 2022 Oddsson, Bisson, Cohen, Iloputaife, Jacobs, Kung, Lipsitz, Manor, McCracken, Rumsey, Wrisley and Koehler-McNicholas. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Oddsson, Lars I. E.
Bisson, Teresa
Cohen, Helen S.
Iloputaife, Ikechukwu
Jacobs, Laura
Kung, Doris
Lipsitz, Lewis A.
Manor, Brad
McCracken, Patricia
Rumsey, Yvonne
Wrisley, Diane M.
Koehler-McNicholas, Sara R.
Extended effects of a wearable sensory prosthesis on gait, balance function and falls after 26 weeks of use in persons with peripheral neuropathy and high fall risk—The walk2Wellness trial
title Extended effects of a wearable sensory prosthesis on gait, balance function and falls after 26 weeks of use in persons with peripheral neuropathy and high fall risk—The walk2Wellness trial
title_full Extended effects of a wearable sensory prosthesis on gait, balance function and falls after 26 weeks of use in persons with peripheral neuropathy and high fall risk—The walk2Wellness trial
title_fullStr Extended effects of a wearable sensory prosthesis on gait, balance function and falls after 26 weeks of use in persons with peripheral neuropathy and high fall risk—The walk2Wellness trial
title_full_unstemmed Extended effects of a wearable sensory prosthesis on gait, balance function and falls after 26 weeks of use in persons with peripheral neuropathy and high fall risk—The walk2Wellness trial
title_short Extended effects of a wearable sensory prosthesis on gait, balance function and falls after 26 weeks of use in persons with peripheral neuropathy and high fall risk—The walk2Wellness trial
title_sort extended effects of a wearable sensory prosthesis on gait, balance function and falls after 26 weeks of use in persons with peripheral neuropathy and high fall risk—the walk2wellness trial
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531134/
https://www.ncbi.nlm.nih.gov/pubmed/36204554
http://dx.doi.org/10.3389/fnagi.2022.931048
work_keys_str_mv AT oddssonlarsie extendedeffectsofawearablesensoryprosthesisongaitbalancefunctionandfallsafter26weeksofuseinpersonswithperipheralneuropathyandhighfallriskthewalk2wellnesstrial
AT bissonteresa extendedeffectsofawearablesensoryprosthesisongaitbalancefunctionandfallsafter26weeksofuseinpersonswithperipheralneuropathyandhighfallriskthewalk2wellnesstrial
AT cohenhelens extendedeffectsofawearablesensoryprosthesisongaitbalancefunctionandfallsafter26weeksofuseinpersonswithperipheralneuropathyandhighfallriskthewalk2wellnesstrial
AT iloputaifeikechukwu extendedeffectsofawearablesensoryprosthesisongaitbalancefunctionandfallsafter26weeksofuseinpersonswithperipheralneuropathyandhighfallriskthewalk2wellnesstrial
AT jacobslaura extendedeffectsofawearablesensoryprosthesisongaitbalancefunctionandfallsafter26weeksofuseinpersonswithperipheralneuropathyandhighfallriskthewalk2wellnesstrial
AT kungdoris extendedeffectsofawearablesensoryprosthesisongaitbalancefunctionandfallsafter26weeksofuseinpersonswithperipheralneuropathyandhighfallriskthewalk2wellnesstrial
AT lipsitzlewisa extendedeffectsofawearablesensoryprosthesisongaitbalancefunctionandfallsafter26weeksofuseinpersonswithperipheralneuropathyandhighfallriskthewalk2wellnesstrial
AT manorbrad extendedeffectsofawearablesensoryprosthesisongaitbalancefunctionandfallsafter26weeksofuseinpersonswithperipheralneuropathyandhighfallriskthewalk2wellnesstrial
AT mccrackenpatricia extendedeffectsofawearablesensoryprosthesisongaitbalancefunctionandfallsafter26weeksofuseinpersonswithperipheralneuropathyandhighfallriskthewalk2wellnesstrial
AT rumseyyvonne extendedeffectsofawearablesensoryprosthesisongaitbalancefunctionandfallsafter26weeksofuseinpersonswithperipheralneuropathyandhighfallriskthewalk2wellnesstrial
AT wrisleydianem extendedeffectsofawearablesensoryprosthesisongaitbalancefunctionandfallsafter26weeksofuseinpersonswithperipheralneuropathyandhighfallriskthewalk2wellnesstrial
AT koehlermcnicholassarar extendedeffectsofawearablesensoryprosthesisongaitbalancefunctionandfallsafter26weeksofuseinpersonswithperipheralneuropathyandhighfallriskthewalk2wellnesstrial